Skip to main content
OpenTrials

Clinical trial condition

Lung Neoplasms

Explore clinical trials studying Lung Neoplasms. Study availability and eligibility vary by location and protocol.

4,227 public trials 1,016 recruiting studies
Refine in advanced search Browse all conditions

Lung Neoplasms trial results

Completed

Afatinib in NSCLC With HER2 Mutation

NCT02597946

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • Hunan Province Tumor Hospital Changsha, China
  • First Affiliated Hospital of Guangzhou Medical University Guangzhou, China
  • Zhejiang Cancer Hospital Hangzhou, China
  • The Second Affiliated Hospital to Nanchang University Nanchang, China
View Trial Details
Completed

Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)

NCT03669523

Conditions
Bone Metastases, Bronchial Neoplasms, Carcinoma, Bronchogenic, +8 more
Locations
  • CH du Pays d'Aix Aix-en-Provence, France
  • Chu Angers Angers, France
  • Centre Hospitalier de Beauvais Beauvais, France
  • Centre Hospitalier Fleyriat Bourg-en-Bresse, France
View all 27 locations
View Trial Details
Completed

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

NCT01346540

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • 1199.82.39004 Boehringer Ingelheim Investigational Site Milan, Italy
  • 1199.82.3102 Boehringer Ingelheim Investigational Site Maastricht, Netherlands
  • 1199.82.3401 Boehringer Ingelheim Investigational Site Barcelona, Spain
  • 1199.82.3406 Boehringer Ingelheim Investigational Site Madrid, Spain
View Trial Details
Completed

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

NCT02300298

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • 1199.90.81001 Boehringer Ingelheim Investigational Site Chiba , Kashiwa, Japan
  • 1199.90.81003 Boehringer Ingelheim Investigational Site Kanagawa, Yokohama, Japan
  • 1199.90.81007 Boehringer Ingelheim Investigational Site Osaka, Osakasayama, Japan
  • 1199.90.81006 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan
View Trial Details
Completed

Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2

NCT02733159

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • The Christie NHS Foundation Trust Manchester, Greater Manchester, United Kingdom
  • Southampton University Hospitals NHS Trust Southampton, Hampshire, United Kingdom
  • Maidstone and Tunbridge Wells NHS Trust Maidstone, Kent, United Kingdom
  • University Hospital Birmingham NHS Foundation Trust Birmingham, West Midlands, United Kingdom
View Trial Details
Completed

Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT03358875

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Hospital de Amor Barretos Barretos, Brazil
  • Hospital Evangelico de Cachoeiro de Itapemirim Cachoeiro de Itapemirim, Brazil
  • Hospital Haroldo Juacaba Instituto Do Cancer Do Ceara Fortaleza, Brazil
  • Oncosite Centro de Pesquisa Clinica Em Oncologia Ijuí, Brazil
View all 121 locations
View Trial Details

Related conditions